221 related articles for article (PubMed ID: 28223694)
1. Combination of ruthenium(II)-arene complex [Ru(η
Berndsen RH; Weiss A; Abdul UK; Wong TJ; Meraldi P; Griffioen AW; Dyson PJ; Nowak-Sliwinska P
Sci Rep; 2017 Feb; 7():43005. PubMed ID: 28223694
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains.
Nowak-Sliwinska P; Clavel CM; Păunescu E; te Winkel MT; Griffioen AW; Dyson PJ
Mol Pharm; 2015 Aug; 12(8):3089-96. PubMed ID: 26158308
[TBL] [Abstract][Full Text] [Related]
3. Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
Nowak-Sliwinska P; van Beijnum JR; Casini A; Nazarov AA; Wagnieres G; van den Bergh H; Dyson PJ; Griffioen AW
J Med Chem; 2011 Jun; 54(11):3895-902. PubMed ID: 21534534
[TBL] [Abstract][Full Text] [Related]
4. Anti-metastatic effects of RAPTA-C conjugated polymeric micelles on two-dimensional (2D) breast tumor cells and three-dimensional (3D) multicellular tumor spheroids.
Lu H; Blunden BM; Scarano W; Lu M; Stenzel MH
Acta Biomater; 2016 Mar; 32():68-76. PubMed ID: 26689468
[TBL] [Abstract][Full Text] [Related]
5. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways.
Chatterjee S; Kundu S; Bhattacharyya A; Hartinger CG; Dyson PJ
J Biol Inorg Chem; 2008 Sep; 13(7):1149-55. PubMed ID: 18597125
[TBL] [Abstract][Full Text] [Related]
6. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.
Weiss A; Ding X; van Beijnum JR; Wong I; Wong TJ; Berndsen RH; Dormond O; Dallinga M; Shen L; Schlingemann RO; Pili R; Ho CM; Dyson PJ; van den Bergh H; Griffioen AW; Nowak-Sliwinska P
Angiogenesis; 2015 Jul; 18(3):233-44. PubMed ID: 25824484
[TBL] [Abstract][Full Text] [Related]
7. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
[TBL] [Abstract][Full Text] [Related]
9. Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T.
Nhukeaw T; Hongthong K; Dyson PJ; Ratanaphan A
Apoptosis; 2019 Aug; 24(7-8):612-622. PubMed ID: 31016421
[TBL] [Abstract][Full Text] [Related]
10. A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles.
Lu M; Henry CE; Lai H; Khine YY; Ford CE; Stenzel MH
Biomater Sci; 2019 Mar; 7(4):1652-1660. PubMed ID: 30724288
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
[TBL] [Abstract][Full Text] [Related]
12. Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand.
Egger AE; Hartinger CG; Renfrew AK; Dyson PJ
J Biol Inorg Chem; 2010 Aug; 15(6):919-27. PubMed ID: 20364440
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Antimetastatic Activity of the Ruthenium Anticancer Drug RAPTA-C Delivered in Fructose-Coated Micelles.
Lu M; Chen F; Noy JM; Lu H; Stenzel MH
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28234423
[TBL] [Abstract][Full Text] [Related]
14. Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
Ratanaphan A; Nhukeaw T; Hongthong K; Dyson PJ
Anticancer Agents Med Chem; 2017; 17(2):212-220. PubMed ID: 27039925
[TBL] [Abstract][Full Text] [Related]
15. Fine-tuning the cytotoxicity of ruthenium(II) arene compounds to enhance selectivity against breast cancers.
Pereira SAP; Romano-deGea J; Barbosa AI; Costa Lima SA; Dyson PJ; Saraiva MLMFS
Dalton Trans; 2023 Aug; 52(33):11679-11690. PubMed ID: 37552495
[TBL] [Abstract][Full Text] [Related]
16.
Gopalakrishnan D; Saravanan S; Merckx R; Madan Kumar A; Khamrang T; Velusamy M; Vasanth K; Sunitha S; Hoogenboom R; Maji S; Ganeshpandian M
Dalton Trans; 2021 Jun; 50(23):8232-8242. PubMed ID: 34037018
[TBL] [Abstract][Full Text] [Related]
17. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
18. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Aird RE; Cummings J; Ritchie AA; Muir M; Morris RE; Chen H; Sadler PJ; Jodrell DI
Br J Cancer; 2002 May; 86(10):1652-7. PubMed ID: 12085218
[TBL] [Abstract][Full Text] [Related]
20. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
